453 related articles for article (PubMed ID: 30254092)
21. Bcl-2 and Bcl-xL mediate resistance to receptor tyrosine kinase-targeted therapy in lung and gastric cancer.
Jin J; Xiong Y; Cen B
Anticancer Drugs; 2017 Nov; 28(10):1141-1149. PubMed ID: 28885267
[TBL] [Abstract][Full Text] [Related]
22. Histone Deacetylase Inhibitor Enhances the Efficacy of MEK Inhibitor through NOXA-Mediated MCL1 Degradation in Triple-Negative and Inflammatory Breast Cancer.
Torres-Adorno AM; Lee J; Kogawa T; Ordentlich P; Tripathy D; Lim B; Ueno NT
Clin Cancer Res; 2017 Aug; 23(16):4780-4792. PubMed ID: 28465444
[No Abstract] [Full Text] [Related]
23. Cisplatin-induced apoptosis in non-small-cell lung cancer cells is dependent on Bax- and Bak-induction pathway and synergistically activated by BH3-mimetic ABT-263 in p53 wild-type and mutant cells.
Matsumoto M; Nakajima W; Seike M; Gemma A; Tanaka N
Biochem Biophys Res Commun; 2016 Apr; 473(2):490-6. PubMed ID: 26996126
[TBL] [Abstract][Full Text] [Related]
24. mTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1.
Faber AC; Coffee EM; Costa C; Dastur A; Ebi H; Hata AN; Yeo AT; Edelman EJ; Song Y; Tam AT; Boisvert JL; Milano RJ; Roper J; Kodack DP; Jain RK; Corcoran RB; Rivera MN; Ramaswamy S; Hung KE; Benes CH; Engelman JA
Cancer Discov; 2014 Jan; 4(1):42-52. PubMed ID: 24163374
[TBL] [Abstract][Full Text] [Related]
25. Failure to induce apoptosis via BCL-2 family proteins underlies lack of efficacy of combined MEK and PI3K inhibitors for KRAS-mutant lung cancers.
Hata AN; Yeo A; Faber AC; Lifshits E; Chen Z; Cheng KA; Walton Z; Sarosiek KA; Letai A; Heist RS; Mino-Kenudson M; Wong KK; Engelman JA
Cancer Res; 2014 Jun; 74(11):3146-56. PubMed ID: 24675361
[TBL] [Abstract][Full Text] [Related]
26. CDK inhibitors upregulate BH3-only proteins to sensitize human myeloma cells to BH3 mimetic therapies.
Chen S; Dai Y; Pei XY; Myers J; Wang L; Kramer LB; Garnett M; Schwartz DM; Su F; Simmons GL; Richey JD; Larsen DG; Dent P; Orlowski RZ; Grant S
Cancer Res; 2012 Aug; 72(16):4225-37. PubMed ID: 22693249
[TBL] [Abstract][Full Text] [Related]
27. TIC10/ONC201 synergizes with Bcl-2/Bcl-xL inhibition in glioblastoma by suppression of Mcl-1 and its binding partners in vitro and in vivo.
Karpel-Massler G; Bâ M; Shu C; Halatsch ME; Westhoff MA; Bruce JN; Canoll P; Siegelin MD
Oncotarget; 2015 Nov; 6(34):36456-71. PubMed ID: 26474387
[TBL] [Abstract][Full Text] [Related]
28. Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer.
Molina-Arcas M; Moore C; Rana S; van Maldegem F; Mugarza E; Romero-Clavijo P; Herbert E; Horswell S; Li LS; Janes MR; Hancock DC; Downward J
Sci Transl Med; 2019 Sep; 11(510):. PubMed ID: 31534020
[TBL] [Abstract][Full Text] [Related]
29. Combination treatment with MEK and AKT inhibitors is more effective than each drug alone in human non-small cell lung cancer in vitro and in vivo.
Meng J; Dai B; Fang B; Bekele BN; Bornmann WG; Sun D; Peng Z; Herbst RS; Papadimitrakopoulou V; Minna JD; Peyton M; Roth JA
PLoS One; 2010 Nov; 5(11):e14124. PubMed ID: 21124782
[TBL] [Abstract][Full Text] [Related]
30. MCL1 and BCL-xL levels in solid tumors are predictive of dinaciclib-induced apoptosis.
Booher RN; Hatch H; Dolinski BM; Nguyen T; Harmonay L; Al-Assaad AS; Ayers M; Nebozhyn M; Loboda A; Hirsch HA; Zhang T; Shi B; Merkel CE; Angagaw MH; Wang Y; Long BJ; Lennon XQ; Miselis N; Pucci V; Monahan JW; Lee J; Kondic AG; Im EK; Mauro D; Blanchard R; Gilliland G; Fawell SE; Zawel L; Schuller AG; Strack P
PLoS One; 2014; 9(10):e108371. PubMed ID: 25289887
[TBL] [Abstract][Full Text] [Related]
31. BCL2 induced by LAMTOR3/MAPK is a druggable target of chemoradioresistance in mesenchymal lung cancer.
Kwon OS; Hong SK; Kwon SJ; Go YH; Oh E; Cha HJ
Cancer Lett; 2017 Sep; 403():48-58. PubMed ID: 28606806
[TBL] [Abstract][Full Text] [Related]
32. Confounding off-target effects of BH3 mimetics at commonly used concentrations: MIM1, UMI-77, and A-1210477.
Mallick DJ; Soderquist RS; Bates D; Eastman A
Cell Death Dis; 2019 Feb; 10(3):185. PubMed ID: 30796196
[TBL] [Abstract][Full Text] [Related]
33. Bcl-2/Bcl-xL inhibition increases the efficacy of MEK inhibition alone and in combination with PI3 kinase inhibition in lung and pancreatic tumor models.
Tan N; Wong M; Nannini MA; Hong R; Lee LB; Price S; Williams K; Savy PP; Yue P; Sampath D; Settleman J; Fairbrother WJ; Belmont LD
Mol Cancer Ther; 2013 Jun; 12(6):853-64. PubMed ID: 23475955
[TBL] [Abstract][Full Text] [Related]
34. A Novel Combination Treatment Targeting BCL-X
Cho SY; Han JY; Na D; Kang W; Lee A; Kim J; Lee J; Min S; Kang J; Chae J; Kim JI; Park H; Lee WS; Lee C
Mol Cancer Ther; 2017 Oct; 16(10):2178-2190. PubMed ID: 28611106
[TBL] [Abstract][Full Text] [Related]
35. BH3 mimetics selectively eliminate chemotherapy-induced senescent cells and improve response in TP53 wild-type breast cancer.
Shahbandi A; Rao SG; Anderson AY; Frey WD; Olayiwola JO; Ungerleider NA; Jackson JG
Cell Death Differ; 2020 Nov; 27(11):3097-3116. PubMed ID: 32457483
[TBL] [Abstract][Full Text] [Related]
36. Dynamic BH3 profiling identifies active BH3 mimetic combinations in non-small cell lung cancer.
Potter DS; Du R; Bhola P; Bueno R; Letai A
Cell Death Dis; 2021 Jul; 12(8):741. PubMed ID: 34315868
[TBL] [Abstract][Full Text] [Related]
37. Sorafenib Sensitizes Glioma Cells to the BH3 Mimetic ABT-737 by Targeting MCL1 in a STAT3-Dependent Manner.
Kiprianova I; Remy J; Milosch N; Mohrenz IV; Seifert V; Aigner A; Kögel D
Neoplasia; 2015 Jul; 17(7):564-73. PubMed ID: 26297434
[TBL] [Abstract][Full Text] [Related]
38. Targeting antioxidant enzymes enhances the therapeutic efficacy of the BCL-X
Oh Y; Jung HR; Min S; Kang J; Jang D; Shin S; Kim J; Lee SE; Sung CO; Lee WS; Lee C; Jeong EM; Cho SY
Cancer Lett; 2021 Jan; 497():123-136. PubMed ID: 33068701
[TBL] [Abstract][Full Text] [Related]
39. Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias.
Thijssen R; Diepstraten ST; Moujalled D; Chew E; Flensburg C; Shi MX; Dengler MA; Litalien V; MacRaild S; Chen M; Anstee NS; Reljić B; Gabriel SS; Djajawi TM; Riffkin CD; Aubrey BJ; Chang C; Tai L; Xu Z; Morley T; Pomilio G; Bruedigam C; Kallies A; Stroud DA; Bajel A; Kluck RM; Lane SW; Schoumacher M; Banquet S; Majewski IJ; Strasser A; Roberts AW; Huang DCS; Brown FC; Kelly GL; Wei AH
Blood; 2021 May; 137(20):2721-2735. PubMed ID: 33824975
[TBL] [Abstract][Full Text] [Related]
40. Cotargeting a MYC/eIF4A-survival axis improves the efficacy of KRAS inhibitors in lung cancer.
Nardi F; Perurena N; Schade AE; Li ZH; Ngo K; Ivanova EV; Saldanha A; Li C; Gokhale PC; Hata AN; Barbie DA; Paweletz CP; Jänne PA; Cichowski K
J Clin Invest; 2023 Aug; 133(16):. PubMed ID: 37384411
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
